Sign inCreate account

Report workspace tools

NCT00321620COMPLETEDanonymous

A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer

Sponsor

Source record

Amgen

Phase

Source record

PHASE3

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

zoledronic acid, denosumab

Indication / condition

AI-normalized

Bone Metastases

Intervention

Source record

zoledronic acid, denosumab

Source & freshness

Source record

NCT ID

NCT00321620

Original source

ClinicalTrials.gov

Source last updated

Aug 29, 2018

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00321620

Title

A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer

Sponsor

Amgen

Status

COMPLETED

Phase

PHASE3

Condition raw

Bone Metastases

Condition normalized

Bone Metastases

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

zoledronic acid, denosumab

Target normalized

zoledronic acid, denosumab

Interventions

zoledronic acid, denosumab

Public preview

Source record

The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases in men with hormone-refractory prostate cancer

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00321620

Status

COMPLETED

Phase

PHASE3

Sponsor

Amgen

Executive brief

Investment-Ready Snapshot

The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases in men with hormone-refractory prostate cancer

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedAug 29, 2018
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00321620

Indication

Bone Metastases

Modality

monoclonal antibody

Target

zoledronic acid, denosumab

Intervention

zoledronic acid, denosumab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.